Fig. 3

TMED3 promotes proliferation, migration and invasion in breast cancer cell lines. a, b Stable knock-down of TMED3 was shown to markedly impair the proliferation in MCF-7 and MDA-MB-231 cell lines, as exemplified by MTT assays; **p < 0.01, ***p < 0.001 in comparison with control group using independent sample T-test method; c, d clonogenic abilities were shown to be remarkably suppressed after TMED was being stably silenced in MCF-7 and MDA-MB-231 cell lines, as detected by clonogenesis. **p < 0.01, ***p < 0.001 compared with control group using independent sample T-test; e, f migration was significantly slowed down after TMED being stably knocked down in MCF-7 and MDA-MB-231 cell lines, as detected by wound-healing assays. **p < 0.01 relative to control group using independent sample T-test; g, h similarly, invasion was also inhibited when TMED3 was stably silenced in MCF-7 and MDA-MB-231 cell lines, as evaluated by Transwell assays.*p < 0.05, **p < 0.01 compared with control group using independent sample T-test. All experiments were performed independently three times and presented were the representative figures among candidates